GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Regeneron Pharmaceuticals, Inc. (REGN) [hlAlert]

Rating:
Buy REGN
up 3,119.62 %

Regeneron Pharmaceuticals, Inc. (REGN) rated Buy by Merriman Curhan Ford

Posted on: Friday,  Oct 24, 2008  8:25 AM ET by Merriman Curhan Ford

Merriman Curhan Ford rated Buy Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on 10/24/2008, when the stock price was $16.71.
Since then, Regeneron Pharmaceuticals, Inc. has gained 3119.63% as of 01/27/2016's recent price of $538.00.
If you would have followed this Merriman Curhan Ford's recommendation on REGN, you would have gained 3119.62% of your investment in 2651 days.

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)

We occupy a unique niche among our investment banking peers: we offer our clients both traditional sell-side equity research and primary market research, and we focus on high-potential sectors such as CleanTech, Consumer/Internet/Media, Health Care and Tech/Telecom. Our institutional and corporate clients get the best of both worlds: expertise from our analysts and access to experts through our Panel Intelligence platform.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/24/2008 8:25 AM Buy
None
16.71
as of 12/24/2008
1 Week down  -1.59 %
1 Month down  -6.02 %
3 Months down  -29.52 %
1 YTD down  -29.52 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy